Amen Nidan. Our PM trials are literally living, breathing, growing bodies of data part and parsing good and bad, needed and unneeded data. The timelines of trials with which you speak are arbitrary old archaic “checkpoints” of old failed trial structures. It appears to me that as patients role into OLE their is a continued collection of the why’s and whats next. Like Dr M mentioned a while back “just because your a comt sig1 doesnt mean your not doing better in the trial” (paraphrased) . I truly believe we are going to hear about good benefits in patients in our PDD trial. More symptomatic relief growing the body of evidence of cellular homeostasis. As investors we want tangible proof, black and white but for those living with the diseases we are testing they are alright with coming out of the “black” and some may quite enjoy the “grey” compared to where they were before. Its a process so I am going to give TGD a break. Anyone who is looking to partner with us is going to have to not only do so for the drug but for the process we are developing as well including patents we hold with ariana.
May God continue to bless Anavex, the USA, and our President and his recovery.
Tred